Outsourcing strategy
Assessing the most appropriate outsourcing model for the company's development stage, clinical programme and internal resources.
Investor Advisory
Portfolio biotech support.
Independent commercial and operational support to protect investment value and strengthen clinical trial delivery.
— Overview
Supporting clinical execution after investment.
Following investment, attention turns to delivering the clinical milestones that underpin the company's value.
Many clinical-stage biotech companies operate with lean internal teams and depend heavily on CROs and specialist vendors to execute their development programmes. Effective outsourcing decisions, commercial arrangements and oversight are therefore critical to managing costs, timelines and delivery risks.
Henley Biotech Partners works alongside investors and portfolio company management, providing senior-level expertise in clinical outsourcing, CRO selection, commercial negotiations and vendor governance.
Our role is to strengthen existing capabilities, improve visibility of delivery risks and help ensure that clinical development expenditure is managed effectively.
— How we help
How we support portfolio companies
CRO selection and evaluation
Supporting structured CRO selection processes to identify providers with the capabilities, experience and commercial approach best suited to the programme.
CRO proposals, budgets and contracts
Reviewing proposals, challenging commercial assumptions and supporting negotiations to improve contractual clarity, cost visibility and commercial protections.
CRO oversight and governance
Establishing appropriate vendor oversight, performance monitoring and escalation arrangements to strengthen management control of outsourced clinical activities.
Investor and board reporting
Supporting clear reporting on CRO performance, clinical delivery milestones, expenditure and emerging operational or commercial risks.
Study recovery and CRO performance
Providing independent commercial and operational support where a clinical trial or CRO relationship is experiencing difficulties, including assessment of corrective actions and potential provider transitions.
— How we work
Flexible senior support, when it matters.
Henley can support individual decisions, such as a CRO selection or contract negotiation, or work alongside portfolio company leadership over a defined period during a critical phase of clinical development.
Engagements are tailored to the needs of the investor and management team, providing experienced commercial and outsourcing expertise without the commitment of a permanent senior appointment.
Our objective is to strengthen decision-making, improve oversight and help protect the capital invested in clinical development.
— FAQ
Frequently asked questions.
Who engages Henley: the investor or the portfolio company?
Either. We can be engaged directly by an investor or by the portfolio company, with the scope, responsibilities and reporting arrangements agreed at the outset. We work collaboratively with management while maintaining clear accountability to the commissioning client.
Do you replace the internal clinical operations team?
No. Henley complements existing clinical operations and management teams, providing additional senior expertise in CRO outsourcing, commercial arrangements, vendor management and governance.
Can you support a company following an investment due diligence engagement?
Yes. Where Henley has supported an investor during due diligence, we can provide continuity after investment, helping management address identified outsourcing, commercial or delivery risks.
Can you help when a clinical study is experiencing difficulties?
Yes. We can independently review CRO performance, commercial commitments and governance arrangements, support discussions with providers and help develop practical corrective actions or transition options.
Supporting a clinical-stage biotech investment?
Access independent, senior-level CRO and outsourcing expertise to strengthen clinical delivery and manage commercial risk.
Arrange a confidential discussion→